Skip to content

US · RKDA · AGRICULTURAL INPUTS

Arcadia Biosciences, Inc. (RKDA) intrinsic value and stock valuation

$0.17as of 2026-11-21 · Mkt cap 1.09M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Arcadia Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values RKDA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RKDA’s statements →

Arcadia Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Basic Materials · Agricultural Inputs Davis, TX 75225 arcadiabio.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$4.86M-9.6% 5y CAGRd
20122025
Net income
-$-2.34M
20122025
Free cash flow
-$-4.74M
20122025
Total equity
$4.14M-32% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$4.86M$5.04M$4.45M$7.42M$6.78M
Operating income-$-9.99M-$-3.65M-$-6.1M-$-14.01M-$-35.53M
Net income-$-2.34M-$-7.04M-$-13.98M-$-15.38M-$-14.66M
EPSd-$-1.71M-$-5.18M-$-11.27M-$-25.63M-$-27.66M
Operating cash flow-$-4.74M-$-9.63M-$-15.29M-$-13.98M-$-25.87M
Capital expenditure$0.00-$-20K-$-10K-$-70K-$-1.01M
Free cash flow-$-4.74M-$-9.64M-$-15.3M-$-14.05M-$-26.88M
Total assets$6.55M$13.5M$19.7M$28.9M$43.9M
Total debt$0.00$150K$1.01M$2.02M$3.29M
Net debt-$-260K-$-4.09M-$-5.51M-$-18.63M-$-25.39M
Total equity$4.14M$6.22M$12.7M$20.9M$31.2M
Cash and short-term investments$4.56M$4.24M$11.6M$20.6M$28.7M
Income statement
20252024202320222021
Revenue$4.86M$5.04M$4.45M$7.42M$6.78M
Cost of revenue$3.1M$2.96M$2.17M$6.1M$8.71M
Gross profit$1.76M$2.08M$2.28M$1.32M-$-1.93M
Research and development expenses$10K$50K$60K$1.51M$3.89M
Selling, general and administrative expenses$7M$9.64M$8.23M$15M$22.9M
Other expenses$4.75M-$-3.96M$80K-$-1.22M$6.77M
Operating expenses$11.8M$5.73M$8.38M$15.3M$33.6M
Cost and expenses$14.9M$8.69M$10.6M$21.4M$42.3M
Interest income$220K$780K$690K$290K$0.00
Interest expense$0.00$0.00$0.00$0.00$20K
Depreciation and amortization$30K$110K$290K$480K$1.04M
Ebitda-$-2.3M-$-7.5M-$-5.73M-$-14.75M-$-27.71M
Operating income-$-9.99M-$-3.65M-$-6.1M-$-14.01M-$-35.53M
Total other income/expenses, net$7.66M-$-660K$780K$3.19M$19.4M
Income before tax-$-2.33M-$-4.31M-$-5.32M-$-10.81M-$-16.13M
Income tax expense$10K$10K$10K$10K$0.00
Net income-$-2.34M-$-7.04M-$-13.98M-$-15.38M-$-14.66M
Weighted average shares outstanding$1.37M$1.36M$1.24M$600K$530K
Weighted average diluted shares outstanding$1.37M$1.36M$1.24M$600K$530K
Balance sheet
20252024202320222021
Cash and short-term investments$4.56M$4.24M$11.6M$20.6M$28.7M
Net receivables$420K$1.18M$510K$1.22M$1.37M
Inventory$1.21M$900K$1.96M$2.32M$4.43M
Total current assets$6.36M$9.24M$15M$25.4M$35.4M
Property, plant and equipment, net$10K$180K$1.18M$2.53M$5.37M
Goodwill and intangible assets$40K$40K$40K$40K$480K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$190K$4.28M$4.73M$3.52M$8.53M
Total assets$6.55M$13.5M$19.7M$28.9M$43.9M
Accounts payable$1.45M$700K$800K$910K$1.41M
Short-term debt$0.00$150K$850K$1.01M$1.07M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.06M$2.56M$3.59M$4.21M$5.04M
Long-term debt$0.00$0.00$150K$1.01M$2.22M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$350K$4.73M$3.41M$3.81M$7.68M
Capital lease obligations$0.00$150K$1.01M$2.02M$3.29M
Total liabilities$2.41M$7.29M$7M$8.02M$12.7M
Common stock$70K$70K$70K$70K$60K
Retained earnings-$-281.22M-$-278.88M-$-271.84M-$-257.86M-$-226.49M
Accumulated other comprehensive income (loss)$0.00$0.00$100K$0.00$0.00
Total equity$4.14M$6.22M$12.7M$20.9M$31.2M
Total investments$4.3M$0.00$5.12M$0.00$0.00
Total debt$0.00$150K$1.01M$2.02M$3.29M
Net debt-$-260K-$-4.09M-$-5.51M-$-18.63M-$-25.39M
Cash flow statement
20252024202320222021
Net income-$-2.34M-$-4.32M-$-13.99M-$-15.61M-$-16.13M
Depreciation and amortization$30K$770K$290K$480K$1.04M
Stock-based compensation$230K$0.00$720K$1.11M$1.54M
Change in working capital-$-30K-$-1.45M-$-2.74M$1.05M-$-2.92M
Accounts receivable$170K-$-760K$180K$590K-$-40K
Inventory-$-310K$550K-$-2.42M$1.12M-$-2.38M
Accounts payable-$-400K-$-300K-$-520K-$-760K-$-370K
Net cash provided by operating activities-$-4.74M-$-9.63M-$-15.29M-$-13.98M-$-25.87M
Investments in property, plant and equipment$0.00-$-2.02M-$-10K-$-70K-$-1.01M
Acquisitions, net$0.00$330K$570K$570K-$-4.25M
Net cash used for investing activities$750K$7.34M-$-4.34M$1.42M$16.6M
Common stock issued$10K$10K$6M$5M$25.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10K$10K$5.51M$4.52M$21.9M
Net change in cash-$-3.98M-$-2.28M-$-14.13M-$-8.04M$12.6M
Cash at end of period$260K$4.24M$6.52M$20.6M$28.7M
Operating cash flow-$-4.74M-$-9.63M-$-15.29M-$-13.98M-$-25.87M
Capital expenditure$0.00-$-20K-$-10K-$-70K-$-1.01M
Free cash flow-$-4.74M-$-9.64M-$-15.3M-$-14.05M-$-26.88M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Arcadia Biosciences, Inc.

        Arcadia Biosciences, Inc. is a U.S.-based company that provides plant-derived health and well-being products. Additionally, it is actively engaged in agricultural research and development, with a particular focus on improving wheat crops. The aim of these innovations is to enhance farmers' economic stability by boosting crop performance in the field, increasing their value for food and wellness applications, and expanding their potential for industrial uses. Established in 2002, the company's main office is located in Davis, California.

        CEO
        Thomas J. Schaefer
        Employees
        8
        Beta
        0.54

        Explore

        Frequently asked questions

        What is the intrinsic value of Arcadia Biosciences, Inc. (RKDA)?

        InvestorsCraft does not currently publish an intrinsic value for RKDA. How the IC value is calculated.

        Is RKDA undervalued?

        InvestorsCraft does not publish an undervaluation signal for RKDA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.